SCHEMBL4160883

SCHEMBL4160883

CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N\OC)c4ccc(C#N)cc4)ccc32)cc1)C(=O)O

nearest known ligand 0.87

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 20/20 0.87
PPARA Q07869 19/20 0.87
PPARD Q03181 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4160889 1.00 PPARG (0.87) PPARGPPARAPPARD
SCHEMBL4146970 0.93 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL4144248 0.93 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL4146973 0.93 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL4144941 0.93 PPARG (0.92) PPARGPPARAPPARD
SCHEMBL4144946 0.93 PPARG (0.92) PPARGPPARAPPARD
SCHEMBL4144244 0.93 PPARG (1.00) PPARGPPARAPPARD
SCHEMBL5271362 0.90 PPARG (0.70) PPARGPPARAPPARD
SCHEMBL5320006 0.87 PPARG (0.92) PPARGPPARA
SCHEMBL4156950 0.87 PPARG (1.00) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124656-A1 Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them LES LABORATOIRES SERVIER (FR) 2009-05-14 US claimed
US-20090124656-A1 Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them LES LABORATOIRES SERVIER (FR) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124656-A1 Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them GPR119, HBB, CYP3A7 PPARG 969/4885PPARA 1020/4885PPARD 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.